ACHN : Analysis & Opinions

  1. Johnson & Johnson Seeks to Deliver 10 Blockbusters

    May 22, 2015
    Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) might be stuck in a bit of a trading range over the past year, ...
  2. 3 Under-the-Radar Risks for Gilead Sciences

    March 27, 2015
    Put mildly, biotechnology company Gilead Sciences (NASDAQ: GILD) is nothing short of a cash flow behemoth. Over the past ...
  3. Like Volatility? Trade These Four Stocks

    September 3, 2014
    These four stocks have seen wide moves over the last 30 days, offering big short-term potential for those willing to take ...
  4. Buyout Cycle Boosts Biotech ETFs

    June 16, 2014
    The 230% single day gain that IDIX experienced as a result of the buyout had a huge impact on the SPDR Biotechnology ETF ...
  5. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  6. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  7. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!